✦ LIBER ✦

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

✍ Scribed by Katodritou, Eirini; Terpos, Evangelos; Symeonidis, Argiris S.; Pouli, Anastasia; Kelaidi, Charikleia; Kyrtsonis, Marie-Christine; Kotsopoulou, Maria; Delimpasi, Sosana; Christoforidou, Anna; Giannakoulas, Nikolaos; Viniou, Nora-Athina; Stefanoudaki, Ekaterini; Hadjiaggelidou, Christina; Christoulas, Dimitrios; Verrou, Evgenia; Gastari, Vassiliki; Papadaki, Sofia; Polychronidou, Genovefa; Papadopoulou, Athina; Giannopoulou, Evlambia; Kastritis, Efstathios; Kouraklis, Alexandra; Konstantinidou, Pavlina; Anagnostopoulos, Achilles; Zervas, Konstantinos; Dimopoulos, Meletios A.

Book ID: 125834397
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 518 KB
Volume: 89
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.23745

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multiple myeloma in octogenarians: Clini

Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era

✍ Meletios A. Dimopoulos; Efstathios Kastritis; Sossana Delimpasi; Eirini Katodrit 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

“Real-world” data on the efficacy and sa

“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group

✍ Eirini Katodritou, Chrysanthi Vadikolia, Chrysavgi Lalagianni… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 391 KB

Improved Survival for Multiple Myeloma i

Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group

✍ Hans E. Johnsen; Tobias W. Klausen; Martin Boegsted; Stig Lenhoff; Peter Gimsing 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 143 KB

Relapse to prior autograft and chronic g

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ Nicolaus Kröger; Jose A. Perez-Simon; Han Myint; Hans Klingemann; Avichai Shimon 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 289 KB

Circulating angiopoietin-1 to angiopoiet

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

✍ Evangelos Terpos; Konstantinos Anargyrou; Eirini Katodritou; Efstathios Kastriti 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 456 KB 👁 1 views

## Abstract The circulating levels of several angiogenic cytokines [angiopoietin‐1 (Ang‐1), angiopoietin‐2 (Ang‐2), vascular endothelial growth factor (VEGF), angiogenin and basic fibroblast growth factor (bFGF)] were evaluated in 174 consecutive patients with newly diagnosed, symptomatic, multiple

Soluble syndecan-1 level at diagnosis is

Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

✍ Richard Lovell; Janet A. Dunn; Gulnaz Begum; Nicola J. Barth; Tim Plant; Paul A. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB